PISCES III, the study of ReNeuron’s CTX cell therapy candidate for stroke disability, is a randomised, placebo-controlled clinical trial in the US involving 110 patients across 40 clinical trial sites. Patients exhibiting stable post-stroke disability are entered into the study six to 12 months after their stroke.
The objective of PISCES III is to compare the improvement on the Modified Rankin Scale of patients in the treated and placebo arms, six months after treatment compared with baseline. Top-line results from the study are anticipated in early 2020.
Olav Hellebø, CEO of ReNeuron, commented: “We are delighted that the first subject has been treated in the PISCES III stroke clinical trial in the US with our CTX stem cell therapy candidate. No therapeutic interventions are currently available to improve motor function and quality of life for disabled stroke patients. This important clinical trial moves us forward to potentially meeting this very significant unmet need.”